Georgios Trichas
Nessuna posizione attualmente
Storia della carriera di Georgios Trichas
Precedenti posizioni note di Georgios Trichas
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Direttore/Membro del Consiglio | - | - |
Wellcome Trust Ltd. (Direct Investments)
 Wellcome Trust Ltd. (Direct Investments) Investment ManagersFinance Wellcome Trust Ltd. Direct Investments (WTDI) is a private equity and venture capital division of the Wellcome Trust Ltd. The firm was founded in 1936 by Sir Henry Wellcome. It’s headquartered in London, UK. | Analista di Private Equity | 11/02/2014 | - |
Formazione di Georgios Trichas
| University of Crete | Graduate Degree |
| University of Oxford | Graduate Degree |
Statistiche
Distribuzione geografica
| Regno Unito | 3 |
| Danimarca | 2 |
| Grecia | 2 |
Posizioni
| Graduate Degree | 2 |
| Private Equity Analyst | 1 |
| Director/Board Member | 1 |
Settori
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Wellcome Trust Ltd. (Direct Investments)
Wellcome Trust Ltd. (Direct Investments) Investment ManagersFinance Wellcome Trust Ltd. Direct Investments (WTDI) is a private equity and venture capital division of the Wellcome Trust Ltd. The firm was founded in 1936 by Sir Henry Wellcome. It’s headquartered in London, UK. | Finance |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Borsa valori
- Insiders
- Georgios Trichas
- Esperienza
